Thomas Wilder joins Endologix's board
This article was originally published in Clinica
Stent graft developer Endologix has appointed Thomas Wilder to its board of directors. Mr Wilder is currently president and CEO of Sequent Medical, a privately-held company that is developing devices for neurovascular disease. He was previously president and CEO of PhotoThera, which is developing transcranial laser therapy for acute ischaemic stroke. Before this, he held similar roles at neurovascular specialist Micro Therapeutics, which was acquired by ev3 in January 2006. He also worked for Medtronic for 11 years in various roles. Mr Wilder replaces Paul McCormick, whose term on the board expired this month.